Get the Stockscreener App
1.42
6.58%
-0.10
Anebulo Pharmaceuticals Inc stock is traded at $1.42, with a volume of 2,422.
It is down -6.58% in the last 24 hours and down -23.66% over the past month.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
See More
Previous Close:
$1.52
Open:
$1.25
24h Volume:
2,422
Relative Volume:
0.29
Market Cap:
$39.42M
Revenue:
-
Net Income/Loss:
$-10.49M
P/E Ratio:
-3.0213
EPS:
-0.47
Net Cash Flow:
$-9.58M
1W Performance:
-6.58%
1M Performance:
-23.66%
6M Performance:
-32.70%
1Y Performance:
-33.95%
1-Day Range:
$1.25
$1.49
1-Week Range:
$1.25
$1.66
52-Week Range:
$1.25
$3.30
Anebulo Pharmaceuticals Inc Stock (ANEB) Company Profile
Name
Anebulo Pharmaceuticals Inc
Sector
Industry
Phone
737 203 5270
Address
JFL CAPITAL MANAGEMENT, LAKEWAY
Compare ANEB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ANEB | 1.415 | 39.42M | 0 | -10.49M | -9.58M | -0.47 |
| VRTX | 447.94 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.25 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.88 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.33 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.61 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Anebulo Pharmaceuticals Inc Stock (ANEB) Latest News
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 - Investing.com
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions - MSN
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates - Defense World
Anebulo Pharma Secures $1.9M NIDA Grant for Cannabis Toxicity Treatment Development | ANEB Stock News - StockTitan
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com UK
Exxaro Resources (OTCMKTS:EXXAY) Share Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
Short Interest in Janone Inc. (NASDAQ:ALTS) Expands By 10.2% - Defense World
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
Anebulo Pharmaceuticals Updates Corporate Presentation - TipRanks
Anebulo To Report Acute Cannabinoid Intoxication Trial Data In June - RTTNews
Benchmark maintains Speculative Buy on Anebulo stock By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals (NASDAQ:ANEB) Earns "Speculative Buy" Rating from Benchmark - MarketBeat
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 27.7% in September - Defense World
Anebulo Pharmaceuticals reports Q4 EPS (5c) vs. (10c) last year - TipRanks
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended June 30, 2024 - Marketscreener.com
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates - Business Wire
Njabulo Blom set to boost Kaizer Chiefs midfield - FarPost
Kirkland Advises Luminate Capital Partners on its Investment in AbsenceSoft - Legal Desire News Network
Amway marks “Amway Health Run 2024” to celebrate Nutrilite’s 90th anniversary - Nation Thailand
Market Movers Monday: KAVL, PRSO, TGL, PNPNF, NVVE Surge on Breaking Developments - openPR
'Survival instinct kicked in': Survivor of Five Points South mass shooting speaks out - Alabama's News Leader
Langley double-shooting kills one, injures another - CityNews Vancouver
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation - Yahoo Finance
One dead, one wounded after 2 men shot in Langley - MSN
Anebulo Pharmaceuticals Secures NIH Grant for Emergency Cannabis Antidote Development - BP Journal
Indian Super League: Anwar Ali cleared to play for East Bengal, say reports - Scroll.in
Anwar Ali receives NOC from AIFFWhen will he make East Bengal debut? - myKhel
Aligos' fatty liver disease treatment meets main goal in mid-stage study - XM
AmaZulu coach Pablo Franco defends Veli Mothwa as Kaizer Chiefs game looms - IOL
Banzai International, Inc. (NASDAQ:BNZI) Sees Large Growth in Short Interest - Defense World
Global X Active Canadian Dividend ETF Common (TSE:HAL) Stock Passes Above 200 Day Moving Average of $20.01 - Defense World
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Growth in Short Interest - MarketBeat
'Very stupid': Man who helped supply gun later used in Auckland CBD shooting sentenced - New Zealand Herald
Driver arrested in Muse homicide wants assault charge dropped - Bowling Green Daily News
Josue is now a KL City legend - New Straits Times
Scilex Holding (NASDAQ:SCLX) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 5.3% - Defense World
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 8.3% - MarketBeat
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update - Defense World
Anebulo Pharmaceuticals Announces New CEO - GuruFocus.com
Can Actinium Pharmaceuticals (ATNM) bounce back from the Regulatory Hurdles - BP Journal
Anebulo Pharmaceuticals (NASDAQ:ANEB) Shares Down 4% - Defense World
Telehealth Innovations (VSEE) on day when Dow loses more than 750 points - BP Journal
After-Market Stock Rise In Anebulo (ANEB) Indicates Potential Shift In Investor Sentiment - Stocks Telegraph
Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal
Anebulo Pharmaceuticals receives NIDA grant for drug development By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals receives NIDA grant for drug development - Investing.com
Anebulo Pharmaceuticals Inc Stock (ANEB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):